Beta Bionics (NASDAQ:BBNX) Stock Rating Lowered by Wall Street Zen

Beta Bionics (NASDAQ:BBNX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “strong sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other research analysts have also recently weighed in on BBNX. Robert W. Baird boosted their price objective on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. Leerink Partners boosted their price objective on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, September 14th. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Truist Financial boosted their price objective on shares of Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, September 24th. Finally, TD Cowen lifted their price objective on shares of Beta Bionics from $18.00 to $21.00 and gave the stock a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus target price of $23.69.

Beta Bionics Price Performance

Shares of NASDAQ BBNX opened at $16.75 on Friday. Beta Bionics has a 52-week low of $8.80 and a 52-week high of $32.71. The stock has a market capitalization of $910.70 million, a P/E ratio of -9.10 and a beta of 3.44. The firm’s 50-day moving average price is $19.11 and its two-hundred day moving average price is $14.89.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. The company had revenue of $35.51 million during the quarter. As a group, equities research analysts expect that Beta Bionics will post -2.03 earnings per share for the current year.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, Director Christy Jones sold 6,430 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $23.00, for a total transaction of $147,890.00. Following the completion of the transaction, the director directly owned 19,564 shares of the company’s stock, valued at approximately $449,972. This trade represents a 24.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Feider sold 6,675 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the transaction, the chief financial officer directly owned 159,378 shares in the company, valued at $3,045,713.58. This trade represents a 4.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 101,943 shares of company stock valued at $1,995,201. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Beta Bionics

A number of institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC purchased a new stake in shares of Beta Bionics in the second quarter valued at about $2,524,000. Bank of America Corp DE bought a new position in shares of Beta Bionics during the second quarter valued at $8,566,000. Man Group plc purchased a new position in shares of Beta Bionics during the second quarter valued at approximately $419,000. Legal & General Group Plc bought a new position in shares of Beta Bionics in the second quarter worth about $62,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Beta Bionics during the second quarter valued at about $172,000.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Quarterly results slightly beat expectations. Beta Bionics reported a third-quarter loss of $0.52 per share, better than the $0.53 consensus estimate, while revenue of $35.51 million exceeded analysts’ expectations of approximately $34.7 million. The company also updated its 2026 guidance, although details were not provided. Beta Bionics third-quarter results
• Positive Sentiment: Analyst sentiment remains generally favorable. Stifel Nicolaus maintained a Buy rating, and several firms have raised price targets. MarketBeat data shows a Moderate Buy consensus and an average target of $23.69, above the recent trading level.
• Neutral Sentiment: Institutional ownership news was mixed but included notable purchases. BlackRock, Bank of America and other investment firms recently initiated or increased positions in Beta Bionics. Such activity may provide some support, but the reported purchases largely reflect earlier quarters rather than a new catalyst.
• Neutral Sentiment: Insiders continued to sell relatively small portions of their holdings. Director Mark Hopman sold 821 shares for about $16,420, while insider Mike Mensinger sold 2,650 shares for approximately $58,300. Both retained substantial positions, limiting the significance of the transactions, though repeated insider selling can weigh on investor sentiment. SEC insider filing
• Negative Sentiment: Multiple law firms reiterated a securities class-action deadline of November 3, 2026. The lawsuit covers investors who purchased BBNX securities from July 30, 2025, through February 24, 2026. The unusually large number of investor-law-firm notices increases legal, reputational and potential financial risks for Beta Bionics.
• Negative Sentiment: The allegations center on FDA compliance and iLet safety disclosures. Notices allege that Beta Bionics did not fully disclose information related to an FDA warning, quality-system issues and more than 18,000 iLet complaints, including potentially serious hypoglycemia incidents. These claims have not been proven, but possible litigation costs, regulatory action or additional product concerns could pressure the stock. Beta Bionics securities class action notice
• Negative Sentiment: Execution risks could cloud future growth. The company has disclosed challenges associated with the commercial launch of its next-generation Mint patch pump, adding uncertainty to its growth outlook.

Beta Bionics Company Profile

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.